PT3815684T - Métodos de redução do risco de um episódio cardiovascular num indivíduo em terapia com estatina - Google Patents

Métodos de redução do risco de um episódio cardiovascular num indivíduo em terapia com estatina

Info

Publication number
PT3815684T
PT3815684T PT202018644T PT20201864T PT3815684T PT 3815684 T PT3815684 T PT 3815684T PT 202018644 T PT202018644 T PT 202018644T PT 20201864 T PT20201864 T PT 20201864T PT 3815684 T PT3815684 T PT 3815684T
Authority
PT
Portugal
Prior art keywords
risk
individual
reducing
methods
statin therapy
Prior art date
Application number
PT202018644T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Amarin Pharmaceuticals Ie Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49784037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3815684(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amarin Pharmaceuticals Ie Ltd filed Critical Amarin Pharmaceuticals Ie Ltd
Publication of PT3815684T publication Critical patent/PT3815684T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
PT202018644T 2012-06-29 2013-06-28 Métodos de redução do risco de um episódio cardiovascular num indivíduo em terapia com estatina PT3815684T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666447P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
PT3815684T true PT3815684T (pt) 2024-09-24

Family

ID=49784037

Family Applications (4)

Application Number Title Priority Date Filing Date
PT202018644T PT3815684T (pt) 2012-06-29 2013-06-28 Métodos de redução do risco de um episódio cardiovascular num indivíduo em terapia com estatina
PT172067142T PT3363433T (pt) 2012-06-29 2013-06-28 Métodos de redução do risco de um episódio cardiovascular num indivíduo em terapia com estatina utilizando éster etílico do ácido eicosapentaenoico
PT241523489T PT4342546T (pt) 2012-06-29 2013-06-28 Éster etílico do ácido eicosapentanoico para utilização na redução do risco de acidente vascular cerebral não-fatal num indivíduo em terapia com estatina
PT241523596T PT4338805T (pt) 2012-06-29 2013-06-28 Éster etílico do ácido eicosapentanoico para utilização na redução do risco de enfarte do miocárdio não fatal num indivíduo em terapia com estatina

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT172067142T PT3363433T (pt) 2012-06-29 2013-06-28 Métodos de redução do risco de um episódio cardiovascular num indivíduo em terapia com estatina utilizando éster etílico do ácido eicosapentaenoico
PT241523489T PT4342546T (pt) 2012-06-29 2013-06-28 Éster etílico do ácido eicosapentanoico para utilização na redução do risco de acidente vascular cerebral não-fatal num indivíduo em terapia com estatina
PT241523596T PT4338805T (pt) 2012-06-29 2013-06-28 Éster etílico do ácido eicosapentanoico para utilização na redução do risco de enfarte do miocárdio não fatal num indivíduo em terapia com estatina

Country Status (42)

Country Link
US (26) US9603826B2 (enExample)
EP (6) EP4556073A3 (enExample)
JP (3) JP2015522029A (enExample)
KR (1) KR20150036252A (enExample)
CN (4) CN111840268A (enExample)
AU (3) AU2013282394B2 (enExample)
BR (1) BR112014032905B1 (enExample)
CA (3) CA3067012C (enExample)
CL (1) CL2014003534A1 (enExample)
CO (1) CO7190236A2 (enExample)
CR (1) CR20140591A (enExample)
CU (1) CU20140151A7 (enExample)
CY (1) CY1123749T1 (enExample)
DK (4) DK4338805T3 (enExample)
DO (1) DOP2014000301A (enExample)
EA (2) EA039108B1 (enExample)
EC (1) ECSP15002815A (enExample)
ES (4) ES3040261T3 (enExample)
FI (3) FI4338805T3 (enExample)
GE (1) GEP201706768B (enExample)
HK (1) HK1204271A1 (enExample)
HR (4) HRP20241269T1 (enExample)
HU (4) HUE053111T2 (enExample)
IL (3) IL275396B2 (enExample)
LT (4) LT3363433T (enExample)
MA (2) MA66493A1 (enExample)
MX (6) MX394764B (enExample)
MY (1) MY187464A (enExample)
NI (1) NI201400155A (enExample)
NZ (5) NZ743706A (enExample)
PE (1) PE20150770A1 (enExample)
PH (1) PH12014502849A1 (enExample)
PL (4) PL4342546T3 (enExample)
PT (4) PT3815684T (enExample)
RS (4) RS65970B1 (enExample)
SG (5) SG10201913647QA (enExample)
SI (4) SI3815684T1 (enExample)
SM (4) SMT202400504T1 (enExample)
TN (1) TN2014000540A1 (enExample)
UA (2) UA118015C2 (enExample)
WO (1) WO2014005013A2 (enExample)
ZA (1) ZA201500040B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
CN102413825A (zh) 2009-04-29 2012-04-11 阿马里纳股份公司 含有epa和心血管剂的药物组合物以及使用其的方法
AU2010241571B2 (en) 2009-04-29 2014-06-26 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
WO2010147994A1 (en) 2009-06-15 2010-12-23 Amarin Pharma, Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
LT3363433T (lt) 2012-06-29 2021-02-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos sutrikimų rizikos sumažinimo būdas subjektui, gydomam statinais, panaudojant eikozapentaeno rūgšties etilo esterį
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
AU2019231703A1 (en) * 2018-03-06 2020-10-22 Regeneron Pharmaceuticals, Inc. Use of PCSK9 inhibitor for reducing cardiovascular risk
KR20210047312A (ko) * 2018-08-17 2021-04-29 애머린 파마슈티칼스 아일랜드 리미티드 스타틴-치료 대상체에서 말초 동맥 혈관재개통에 대한 필요성을 감소시키는 방법
CN113332269A (zh) * 2018-09-24 2021-09-03 阿马里纳药物爱尔兰有限公司 降低受试者的心血管事件的风险的方法
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
US10813612B2 (en) 2019-01-25 2020-10-27 Cleerly, Inc. Systems and method of characterizing high risk plaques
JP2022554020A (ja) 2019-11-12 2022-12-27 アマリン ファーマシューティカルズ アイルランド リミテッド 心房細動および／または心房粗動を患う対象における心血管イベントのリスクを低減する方法
WO2021110549A1 (de) * 2019-12-05 2021-06-10 Inventio Ag Verfahren zur errichtung eines tragwerkes einer fahrtreppe oder eines fahrsteiges
US11969280B2 (en) 2020-01-07 2024-04-30 Cleerly, Inc. Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
WO2021141921A1 (en) 2020-01-07 2021-07-15 Cleerly, Inc. Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
US20220392065A1 (en) 2020-01-07 2022-12-08 Cleerly, Inc. Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
WO2022212655A1 (en) * 2021-03-31 2022-10-06 Amarin Pharmaceuticals Ireland Limited Compositions comprising epa and colchicine and methods of using the same for reducing the risk of cardiovascular events in a subject
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
US20250143657A1 (en) 2022-03-10 2025-05-08 Cleerly, Inc. Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination
US12440180B2 (en) 2022-03-10 2025-10-14 Cleerly, Inc. Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination
US12406365B2 (en) 2022-03-10 2025-09-02 Cleerly, Inc. Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination
US20250217981A1 (en) 2022-03-10 2025-07-03 Cleerly, Inc. Systems, methods, and devices for image-based plaque analysis and risk determination
KR20230143081A (ko) 2022-04-04 2023-10-11 삼성전자주식회사 중성지방 측정 장치 및 방법
WO2025100587A1 (ko) * 2023-11-08 2025-05-15 경상국립대학교병원 경피적 관상동맥중재술 이후 예후 예측에 대한 정보 제공 방법

Family Cites Families (320)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527784B2 (en) 1978-05-26 1983-03-24 Bang, Hans Olaf Dr. Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
JPS57112593A (en) 1980-12-26 1982-07-13 Koken Boring Machine Co Lathe drill
US4377526A (en) 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
US4526902A (en) 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
JPS6135356A (ja) 1984-07-27 1986-02-19 Nippon Oil & Fats Co Ltd 血液脂質脂肪酸の分析方法
EP0347509A1 (en) 1988-06-21 1989-12-27 Century Laboratories Inc. A process of extraction and purification of polyunsaturated fatty acids from natural sources
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
EP0273708B1 (en) 1986-12-26 1994-03-23 Sagami Chemical Research Center Process for production of eicosapentaenoic acid
JPS63185390A (ja) 1987-01-27 1988-07-30 Suntory Ltd 藻類によるエイコサペンタエン酸の製造方法
US5252333A (en) 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IE63225B1 (en) 1988-09-13 1995-04-05 Efamol Holdings Use of fatty acids in the treatment of myalgic encephalomyelitis
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
JP2839276B2 (ja) 1989-01-23 1998-12-16 日本分光工業株式会社 超臨界流体抽出・分離方法及び装置
US5457130A (en) 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
GB8906369D0 (en) 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
CA2043615C (en) 1990-06-04 2001-08-14 Kazuhiko Hata Method of producing eicosapentaenoic acid or the ester derivative thereof
GB9012651D0 (en) 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
JP3103588B2 (ja) 1990-11-16 2000-10-30 持田製薬株式会社 リポプロテイン（ａ）低下剤
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
US5215630A (en) 1991-06-04 1993-06-01 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
WO1993003450A1 (en) 1991-07-30 1993-02-18 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
DE4133694C2 (de) 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
JP3400466B2 (ja) 1991-10-28 2003-04-28 日本水産株式会社 高純度エイコサペンタエン酸またはそのエステルの製造方法
JPH0649479A (ja) 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
US5888541A (en) 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
JPH0692847A (ja) 1992-09-11 1994-04-05 Mochida Pharmaceut Co Ltd 骨粗鬆症治療剤
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
WO1994028891A1 (en) 1993-06-04 1994-12-22 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
GB9318611D0 (en) 1993-09-08 1993-10-27 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
JP3325995B2 (ja) 1994-02-28 2002-09-17 ミサワホーム株式会社 パネル接合構造
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
GB9404483D0 (en) 1994-03-08 1994-04-20 Norsk Hydro As Refining marine oil compositions
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5760081A (en) 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
JP3368100B2 (ja) 1994-06-02 2003-01-20 キヤノン株式会社 静電荷像現像用トナー
AU711482B2 (en) 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
JP2780154B2 (ja) 1995-02-17 1998-07-30 株式会社ヤクルト本社 ヨーグルト
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
JPH0959206A (ja) 1995-08-25 1997-03-04 Nippon Oil & Fats Co Ltd エイコサペンタエン酸およびエイコサペンタエン酸エステルの製造方法
GB9519661D0 (en) 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
US5763496A (en) 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
AU2738497A (en) 1996-04-24 1997-11-12 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US6248398B1 (en) 1996-05-22 2001-06-19 Applied Materials, Inc. Coater having a controllable pressurized process chamber for semiconductor processing
TW425285B (en) 1996-06-10 2001-03-11 Viva America Marketing Inc Fish oil and garlic nutritive supplement
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
IL129367A0 (en) 1996-10-11 2000-02-17 Scotia Holdings Plc Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
EP0843972B1 (en) 1996-11-20 2002-07-31 N.V. Nutricia Nutritional composition comprising fats for the treatment of the metabolic syndrome
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6531150B1 (en) 1997-10-30 2003-03-11 Morishita Jintan Co., Ltd. Encapsulated unsaturated fatty acid substance and method for producing the same
JP2001523694A (ja) 1997-11-25 2001-11-27 ワーナー−ランバート・カンパニー リポタンパク質酸化の阻害
DE69842121D1 (de) 1997-12-10 2011-03-17 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
NZ500703A (en) 1998-11-04 2001-06-29 F Preparation of food-grade marine edible oils by treatment with silica, vacuum steam deodorisation and addition of a herb extract
US20020055529A1 (en) 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
CA2260397A1 (en) 1999-01-29 2000-07-29 Atlantis Marine Inc. Method of converting rendered triglyceride oil from marine sources into bland, stable food oil
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
DE60005152T2 (de) 1999-03-03 2004-07-08 Eurovita A/S Arzneimittel, nahrungszusätze und kosmetische zubereitung enthaltend eine fettsäure und ingwer
DE60034775T3 (de) 1999-03-04 2016-11-24 Suntory Holdings Ltd. Verwendung von Docosapentsäure enthaltendem Material
US20020054871A1 (en) 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
JP2001025519A (ja) 1999-05-11 2001-01-30 Mamiya Op Co Ltd ゴルフクラブ用シャフト
US7112609B2 (en) 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
CA2311974A1 (en) 1999-06-28 2000-12-28 Nisshin Flour Milling Co., Ltd. Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
PT1072198E (pt) 1999-07-28 2008-06-17 Swiss Caps Rechte & Lizenzen Preparado, especialmente para utilização como medicamento e/ou como suplemento alimentar
AU6813700A (en) 1999-08-30 2001-03-26 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
JP4170542B2 (ja) 1999-11-18 2008-10-22 日油株式会社 高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体
EP1125914A1 (en) 2000-02-14 2001-08-22 Nisshin Flour Milling Co., Ltd. Process for separating and purifying eicosapentaenoic acid or its ester
EP1157692B1 (en) 2000-05-22 2005-10-05 Pro Aparts - Investimentos E Consultoria Lda Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
GB0016452D0 (en) 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
JP4391673B2 (ja) 2000-08-08 2009-12-24 花王株式会社 油脂組成物
KR20030069983A (ko) 2000-08-15 2003-08-27 화이자 프로덕츠 인코포레이티드 치료용 조합물
GB0101198D0 (en) 2001-01-17 2001-02-28 Scherer Technologies Inc R P Ingestible compositions containing an odoriferous oil
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
BR0209749A (pt) 2001-05-30 2004-07-27 Laxdale Ltd Coenzima q e epa ou outro ácido graxo essencial
US20120214771A1 (en) 2001-07-27 2012-08-23 Fontini Sampalis Compositions for treatment of cardiometabolic disorders
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
EP1450787A4 (en) 2001-11-15 2006-01-25 Galileo Pharmaceuticals Inc FORMULATIONS AND METHODS FOR THE TREATMENT OR AMELIORATION OF INFLAMMATORY CONDITIONS
ITMI20020269A1 (it) 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
JP2003306690A (ja) 2002-02-18 2003-10-31 Nooburu:Kk 多価不飽和脂肪酸含有油脂組成物
US20030166614A1 (en) 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
AU2003229993B2 (en) 2002-05-03 2008-07-24 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
ES2524000T3 (es) 2002-06-05 2014-12-03 Teva Czech Industries S.R.O. Reducción de la reticulación de la gelatina
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US20040001874A1 (en) 2002-06-24 2004-01-01 Vital Living, Inc. Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
US20040048919A1 (en) 2002-07-02 2004-03-11 Dreon Darlene M. Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
US20060211761A1 (en) 2002-07-08 2006-09-21 Yatendra Kumar Hmg-coa-reductase inhibitors
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
JP4398862B2 (ja) 2002-08-20 2010-01-13 興和株式会社 軟カプセル剤
DE20214847U1 (de) 2002-09-24 2004-02-19 Voss Automotive Gmbh Anschlußvorrichtung für Rohrleitungen
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
AU2003284633B2 (en) 2002-11-22 2008-07-10 Nippon Suisan Kaisha, Ltd. External composition containing polyunsaturated fatty acid or its salt or ester
GB0228079D0 (en) 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
GB0301701D0 (en) 2003-01-24 2003-02-26 Ensay Ltd Psoriasis and Eicosapentaenoic acid
EP1587377A2 (en) 2003-01-31 2005-10-26 The Procter & Gamble Company Means for improving the appearance of mammalian keratinous tissue
WO2004069238A1 (ja) 2003-02-07 2004-08-19 Mochida Pharmaceutical Co., Ltd. くも膜下出血の予後改善剤
JP4570563B2 (ja) 2003-02-21 2010-10-27 持田製薬株式会社 リバビリン／インターフェロン併用療法の副作用軽減剤
EP1603551A2 (en) 2003-03-05 2005-12-14 Solvay Pharmaceuticals GmbH Use of omega-3-fatty acids in the treatment of diabetic patients
CN100415224C (zh) 2003-03-18 2008-09-03 诺瓦提斯公司 包含脂肪酸和氨基酸的组合物
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US6846942B2 (en) 2003-05-20 2005-01-25 David Rubin Method for preparing pure EPA and pure DHA
US7205329B2 (en) 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
EP1637134A4 (en) 2003-06-20 2010-01-27 Mochida Pharm Co Ltd COMPOSITION FOR THE PREVENTION AND TREATMENT OF VARICES
US20050042214A1 (en) 2003-07-15 2005-02-24 Gershwin M. Eric Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
DE60331236D1 (de) 2003-07-24 2010-03-25 Eswaran Krishnan Iyer Orale zusammensetzungen zur behandlung von diabetes
CA2542574C (en) 2003-11-12 2014-03-18 E. I. Du Pont De Nemours And Company Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous plants and yeast
ITMI20032247A1 (it) 2003-11-19 2005-05-20 Tiberio Bruzzese Interazione di derivati polari di composti insaturi con substrati inorganici
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US7022713B2 (en) 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
EP1591114A1 (en) 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US7923043B2 (en) 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
US20050244367A1 (en) 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
CN2724983Y (zh) 2004-05-17 2005-09-14 廖剑立 液压冲床复合油缸四导柱工作台
US20050272095A1 (en) 2004-05-19 2005-12-08 Ppd Biomarker Discovery Sciences, Llc Methods of identifying biomarkers
TW200613009A (en) 2004-06-11 2006-05-01 Ono Pharmaceutical Co Capsule having chewing stability
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413729D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
ITRM20040395A1 (it) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
US20090042979A1 (en) 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
MX2007001553A (es) 2004-08-06 2008-03-07 Transform Pharmaceuticals Inc Nuevas composiciones farmaceuticas de estatina y metodos de tratamiento relacionados.
WO2006017627A2 (en) 2004-08-06 2006-02-16 Barry Sears Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
CA2577345C (en) 2004-08-18 2013-02-19 Hiroki Ueshima Jelly composition
DK1781265T3 (da) 2004-08-25 2010-08-02 Essentialis Inc Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
CA2581816A1 (en) 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
US20100021555A1 (en) 2004-10-15 2010-01-28 Karl Geiringer Compositions containing high omega-3 and low saturated fatty acid levels
FR2878747B1 (fr) 2004-12-03 2007-03-30 Pierre Fabre Medicament Sa Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
JP2008522970A (ja) 2004-12-06 2008-07-03 レリアント ファーマスーティカルズ インコーポレイテッド 脂質療法用のオメガ−３脂肪酸類及び異常脂質血症薬剤
CN101098690A (zh) 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
US20090239927A1 (en) 2004-12-06 2009-09-24 George Bobotas Statin and Omega-3 Fatty Acids For Lipid Therapy
US20070191467A1 (en) 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
US20060135610A1 (en) 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
GB2421909A (en) 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
WO2006073147A1 (ja) 2005-01-04 2006-07-13 Mochida Pharmaceutical Co., Ltd. 脂肪毒性の改善剤
US20080200707A1 (en) 2005-01-04 2008-08-21 Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. Lipotoxicity Relieving Agent
US20090233843A1 (en) 2005-01-10 2009-09-17 Cortendo Invest Ab Methods and compositions for treating diabetes, metabolic syndrome and other conditions
US20060172012A1 (en) 2005-01-28 2006-08-03 Finley John W Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
US20060189682A1 (en) 2005-02-02 2006-08-24 Payne Joseph E Water soluble prodrugs of COX-2 inhibitors
JP2008530250A (ja) 2005-02-17 2008-08-07 メルク エンド カムパニー インコーポレーテッド アテローム性動脈硬化症、脂質代謝異常及び関連症状の治療方法
US20100254951A1 (en) 2005-02-22 2010-10-07 Mochida Pharmaceutical Co., Ltd. Nerve Regeneration Promoting Agent
CA2600429A1 (en) 2005-03-08 2006-09-14 Reliant Pharmaceuticals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
CA2570763C (en) 2005-07-08 2011-08-23 Mochida Pharmaceutical Co., Ltd. Composition for preventing onset of cardiovascular events
JP5134916B2 (ja) 2005-07-08 2013-01-30 持田製薬株式会社 心血管イベント発症予防用組成物
CA2615944A1 (en) 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
RU2290185C1 (ru) 2005-07-26 2006-12-27 Дмитрий Николаевич Мясников Композиция для нормализации липидного обмена и снижения массы тела и способ её получения
CN101252837A (zh) 2005-07-28 2008-08-27 瑞莱恩特医药品有限公司 用二氢吡啶类钙通道阻断剂和Omega-3脂肪酸及其组合产品的治疗
ITMI20051560A1 (it) 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US20090227602A1 (en) 2005-10-28 2009-09-10 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20070105793A1 (en) 2005-11-04 2007-05-10 Curt Hendrix Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease
US20070104779A1 (en) 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
KR101292573B1 (ko) 2005-11-11 2013-08-12 모치다 세이야쿠 가부시키가이샤 젤리 조성물
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
CA2628666A1 (en) 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
EP1968567B1 (en) 2005-12-20 2014-06-18 Cenestra, Llc Omega 3 fatty acid formulations
DK1800675T3 (da) 2005-12-23 2011-09-05 Nutricia Nv Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens
US20090182022A1 (en) 2006-01-05 2009-07-16 Reliant Pharmaceuticals Treatment of Fatty Liver
EP1905424A3 (en) 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
CN103751781A (zh) 2006-02-07 2014-04-30 持田制药株式会社 预防中风复发的组合物
JP5069448B2 (ja) 2006-02-07 2012-11-07 持田製薬株式会社 脳卒中再発予防用組成物
BRPI0707794A2 (pt) 2006-02-14 2011-05-10 Intercept Pharmaceuticals Inc compostos derivados de Ácido biliar, formulaÇÕes e composiÇÕes farmacÊuticas, bem como uso de ditos compostos
CN101437508A (zh) * 2006-03-03 2009-05-20 孟山都技术有限公司 用于改善心血管健康的十八碳四烯酸
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2007128801A1 (en) 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
JP5591469B2 (ja) 2006-05-31 2014-09-17 持田製薬株式会社 多重リスク患者の心血管イベント発症予防用組成物
US20070292501A1 (en) 2006-06-05 2007-12-20 Udell Ronald G Chewable soft gelatin capsules
JP5658876B2 (ja) 2006-07-05 2015-01-28 フォトンズ コーポレーション リミテッド 大規模従属栄養培養領域にて産生される超高純度ｅｐａと極性脂質
WO2008012329A2 (en) 2006-07-28 2008-01-31 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
US20080085911A1 (en) 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
CN101553221A (zh) 2006-10-10 2009-10-07 瑞莱恩特医药品有限公司 用于降低APO-B水平的抑制素和ω-3脂肪酸
JP2010506920A (ja) 2006-10-18 2010-03-04 リライアント・ファーマシューティカルズ・インコーポレイテッド Ｌｐ−ｐｌａ２濃度を減少させるためのオメガ−３脂肪酸
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
US20080125490A1 (en) 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
WO2008088030A1 (ja) 2007-01-17 2008-07-24 Mochida Pharmaceutical Co., Ltd. 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
WO2008091338A1 (en) 2007-01-23 2008-07-31 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
US20080185198A1 (en) 2007-02-02 2008-08-07 Steven Mark Jones Next generation hybrid III parallel/series hybrid system
CA2672513C (en) 2007-02-15 2010-05-25 Centre De Recherche Sur Les Biotechnologies Marines Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
WO2008106787A1 (en) 2007-03-06 2008-09-12 Bioriginal Food & Science Corporation Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
WO2008115529A1 (en) 2007-03-20 2008-09-25 Reliant Pharmaceuticals, Inc. Compositions comprising omega-3 fatty acids and cetp inhibitors
WO2008145170A1 (de) 2007-05-31 2008-12-04 Siemens Aktiengesellschaft Verfahren zum konfigurieren einer automatisierungsanlage
US20080299187A1 (en) 2007-06-01 2008-12-04 Joar Opheim Substances for Reducing Occurence of Major Cardiac Events in Humans
AU2008272135B2 (en) 2007-06-29 2013-10-31 Takeda Pharmaceutical Company Limited Seamless capsule
WO2009043834A1 (en) 2007-10-01 2009-04-09 Neurosearch A/S Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound
US8361534B2 (en) 2007-12-20 2013-01-29 Abbott Laboratories Stable nutritional powder
MX2010006887A (es) 2007-12-20 2010-10-15 Abbott Lab Polvo nutricional estable.
EA201070835A1 (ru) 2008-01-10 2011-02-28 Такеда Фармасьютикал Компани Лимитед Состав капсулы
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
JP2011522913A (ja) 2008-05-15 2011-08-04 プロノヴァ バイオファーマ ノルゲ アーエス オキアミ油加工方法
CA2724983A1 (en) 2008-05-20 2009-11-26 Mochida Pharmaceutical Co., Ltd. Composition for preventing cardiovascular event in high-risk patient
WO2009151116A1 (ja) 2008-06-13 2009-12-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
WO2009151125A1 (ja) 2008-06-13 2009-12-17 持田製薬株式会社 肝障害の診断及び治療
US20110105510A1 (en) 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
CN102088978B (zh) 2008-07-07 2013-12-18 持田制药株式会社 血脂异常症的改善或治疗药
US8979888B2 (en) 2008-07-30 2015-03-17 Acclarent, Inc. Paranasal ostium finder devices and methods
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
WO2010038796A1 (ja) 2008-09-30 2010-04-08 持田製薬株式会社 Ｃ型肝炎治療剤
US20100130608A1 (en) 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
CA2750561C (en) 2009-01-26 2017-10-10 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein c-iii expression
EP2395991B1 (en) 2009-02-10 2013-05-29 Amarin Pharmaceuticals Ireland Limited Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
US8241672B2 (en) 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US20120046251A1 (en) 2009-04-06 2012-02-23 The Regents Of The University Of California Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing
CN102413825A (zh) * 2009-04-29 2012-04-11 阿马里纳股份公司 含有epa和心血管剂的药物组合物以及使用其的方法
AU2010241571B2 (en) 2009-04-29 2014-06-26 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
WO2010134614A1 (ja) 2009-05-22 2010-11-25 持田製薬株式会社 ω３脂肪酸の自己乳化組成物
WO2010147994A1 (en) 2009-06-15 2010-12-23 Amarin Pharma, Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
RU2402326C1 (ru) 2009-06-22 2010-10-27 Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) Способ коррекции инсулинорезистентности при метаболическом синдроме
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
CA2772618C (en) 2009-09-01 2018-08-21 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US9060981B2 (en) 2009-10-16 2015-06-23 Mochida Pharmaceutical Co., Ltd. Marker associated with non-alcoholic steatohepatitis
JP5951489B2 (ja) 2009-10-16 2016-07-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組成物
MY160249A (en) 2010-01-08 2017-02-28 Catabasis Pharmaceuticals Inc Fatty acid fumarate derivatives and their uses
US20110178105A1 (en) 2010-01-15 2011-07-21 E.I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
EP3583849A1 (en) 2010-03-04 2019-12-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
US8846321B2 (en) 2010-03-12 2014-09-30 President And Fellows Of Harvard College Association of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events
US8663704B2 (en) 2010-04-30 2014-03-04 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
GB2480146A (en) 2010-05-05 2011-11-09 St Giles Foods Ltd Fruit or vegetable based edible composition comprising nutritional supplement
ES2710540T5 (es) 2010-06-30 2022-08-26 Mochida Pharm Co Ltd Preparación de compuesto de ácido graso omega-3
WO2012032414A2 (en) 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
US20130260403A1 (en) 2010-10-20 2013-10-03 GlycoMark Inc. Identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers
CN104814950A (zh) 2010-11-09 2015-08-05 持田制药株式会社 血糖值上升抑制剂在制造经口摄取用食品中的应用
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
KR101310710B1 (ko) 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
SG194671A1 (en) 2011-04-27 2013-12-30 Isis Pharmaceuticals Inc Modulation of apolipoprotein ciii (apociii) expression
US20130095179A1 (en) 2011-09-15 2013-04-18 Omthera Pharmaceuticals, Inc. Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US20140323709A1 (en) 2011-12-12 2014-10-30 National Cerebral And Cardiovascular Center Oligonucleotide and therapeutic agent for hyperlipidemia containing same as active ingredient
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
CA2867168A1 (en) 2012-03-30 2013-10-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
TW201347754A (zh) 2012-05-07 2013-12-01 Omthera Pharmaceuticals Inc 史他汀及ω－３脂肪酸之組合物
US9700538B2 (en) 2012-05-15 2017-07-11 Mochida Pharmaceutical Co., Ltd. Cardiovascular disease primary prevention agent for patients having high blood levels of high-sensitivity C-reactive protein
US9452121B2 (en) 2012-05-30 2016-09-27 Clariant International Ltd. Composition containing amino acid surfactants, betaines and N-methyl-N-acylglucamines and having improved foam quality and higher viscosity
US20130324607A1 (en) 2012-06-05 2013-12-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypercholesterolemia
US20140080850A1 (en) 2012-06-05 2014-03-20 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
LT3363433T (lt) * 2012-06-29 2021-02-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos sutrikimų rizikos sumažinimo būdas subjektui, gydomam statinais, panaudojant eikozapentaeno rūgšties etilo esterį
CA2878267A1 (en) 2012-06-29 2014-01-03 Amarin Pharmaceuticals Ireland Limited Methods of treating pediatric metabolic syndrome
US20150157593A1 (en) 2012-06-29 2015-06-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing ldl-p
US20140004183A1 (en) 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects
US20140005265A1 (en) 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating hypertriglyceridemia
CA2886178C (en) 2012-09-28 2020-12-01 Mochida Pharmaceutical Co., Ltd. Composition for reducing new-onset diabetes
EP2719382A1 (en) 2012-10-12 2014-04-16 Mochida Pharmaceutical Co., Ltd. Ethyl Eicosapentanoate and Pharmaceutical Compositions Comprising Ethyl Eicosapentanoate as an Active Ingredient for Use in the Treatment of Non-Alcoholic Steatohepatitis
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20140213648A1 (en) 2012-12-31 2014-07-31 Amarin Pharmaceuticals Ireland Limited Methods of increasing epa blood levels
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140221358A1 (en) 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US20140221676A1 (en) 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
US20140221452A1 (en) 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US20140242216A1 (en) 2013-02-24 2014-08-28 Mead Johnson Nutrition Company Amino Acid And Protein Hydrolysate Based Formulas With A Stable Emulsion System
US20140249214A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Co-administration of warfarin and ethyl eicosapentaenoate
US20140249220A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof
WO2014134466A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited. Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
US20140249225A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
US20140255537A1 (en) 2013-03-11 2014-09-11 Mead Johnson Nutrition Company Nutritional Compositions Containing an Enriched Lipid Fraction and Uses Thereof
US9661874B2 (en) 2013-03-11 2017-05-30 Mead Johnson Nutrition Company Nutritional compositions containing structured fat globules and uses thereof
US20140271907A1 (en) 2013-03-14 2014-09-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and krill oil and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140275252A1 (en) 2013-03-14 2014-09-18 Amarin Pharmaceuticals Ireland Limited Methods of treating traumatic brain injury
SG11201507288UA (en) 2013-03-15 2015-10-29 Mochida Pharm Co Ltd Compositions and methods for treating non-alcoholic steatohepatitis
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014179325A1 (en) 2013-04-29 2014-11-06 Matinas Biopharma, Inc. Omega-3 fatty acid formulations for use as pharmaceutical treatment
US20140357717A1 (en) 2013-06-04 2014-12-04 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
EP3735963B1 (en) 2013-07-18 2023-09-13 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of omega-3 fatty acid
KR102275447B1 (ko) 2013-07-18 2021-07-08 모치다 세이야쿠 가부시키가이샤 ω3 지방산의 자기 유화 조성물
US20150045431A1 (en) 2013-08-06 2015-02-12 Amarin Pharmaceuticals Ireland Limited Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy
US20150051282A1 (en) 2013-08-14 2015-02-19 Amarin Pharmaceuticals Ireland Limited Methods of treating a cardiovascular disorder and/or joint pain in a subject on glucosamine therapy
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US20150073050A1 (en) 2013-09-09 2015-03-12 Amarin Pharmaceuticals Ireland Limited Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof
US20160213639A1 (en) 2013-10-07 2016-07-28 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015066512A1 (en) 2013-10-31 2015-05-07 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2015243239B2 (en) 2014-04-11 2019-11-14 Cymabay Therapeutics, Inc. Treatment of NAFLD and NASH
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US20170213648A1 (en) 2014-08-01 2017-07-27 Western Michigan University Research Foundation Self-supported electronic devices
US20180015038A1 (en) 2015-01-21 2018-01-18 Mochida Pharmaceutical Co., Ltd. Omega-3 fatty acid self-emulsifying composition
MY185428A (en) 2015-01-21 2021-05-19 Mochida Pharm Co Ltd Self-emulsifying composition of ?-3 fatty acid
US20180028480A1 (en) 2015-03-02 2018-02-01 Richard Preston Mason Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
US20170151202A1 (en) 2015-09-09 2017-06-01 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
DK3275438T3 (da) 2016-07-29 2021-01-18 Kowa Co Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US20190054054A1 (en) 2017-08-15 2019-02-21 Amarin Pharmaceuticals Ireland Limited Methods reducing or preventing oxidation of high density lipoprotein (HDL)
US20190054058A1 (en) 2017-08-15 2019-02-21 Amarin Pharmaceuticals Ireland Limited Methods of Treating or Preventing Bone Loss
US20190209506A1 (en) 2018-01-09 2019-07-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of ldl or lipid membranes in a subject in need thereof
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US20190275057A1 (en) 2018-03-06 2019-09-12 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides in a Subject with Reduced Kidney Function and Diabetes Mellitus
KR20210047312A (ko) 2018-08-17 2021-04-29 애머린 파마슈티칼스 아일랜드 리미티드 스타틴-치료 대상체에서 말초 동맥 혈관재개통에 대한 필요성을 감소시키는 방법
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
EP3856171A1 (en) 2018-09-26 2021-08-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution

Also Published As

Publication number Publication date
FI4338805T3 (fi) 2025-09-03
MA50258A1 (fr) 2023-07-31
US20170258755A1 (en) 2017-09-14
MX2015000138A (es) 2015-09-07
IL275396A (en) 2020-07-30
MX2022010507A (es) 2022-09-21
EP4342546B1 (en) 2025-06-04
PL4342546T3 (pl) 2025-11-17
CA3067008C (en) 2021-10-26
US20190076389A1 (en) 2019-03-14
PT3363433T (pt) 2021-02-15
US20170143656A1 (en) 2017-05-25
MX392694B (es) 2025-03-24
MA50258B2 (fr) 2024-05-31
US20190343788A1 (en) 2019-11-14
US20230338323A1 (en) 2023-10-26
US20190083445A1 (en) 2019-03-21
PE20150770A1 (es) 2015-05-16
SG10201703867RA (en) 2017-06-29
PL3363433T3 (pl) 2021-06-14
BR112014032905A2 (pt) 2017-06-27
NZ737380A (en) 2019-05-31
AU2013282394B2 (en) 2018-04-26
IL236376B (en) 2020-09-30
US9693985B2 (en) 2017-07-04
EA201890380A1 (ru) 2018-11-30
CR20140591A (es) 2015-05-06
MX394763B (es) 2025-03-24
DK3815684T3 (da) 2024-10-21
US9603826B2 (en) 2017-03-28
SG10201913647QA (en) 2020-03-30
US20190076388A1 (en) 2019-03-14
HRP20251052T1 (hr) 2025-11-07
HRP20251049T1 (hr) 2025-11-07
NI201400155A (es) 2016-10-11
ZA201500040B (en) 2016-03-30
AU2018204499B2 (en) 2020-09-24
RS65970B1 (sr) 2024-10-31
CL2014003534A1 (es) 2015-06-12
SI3363433T1 (sl) 2021-05-31
US10383840B2 (en) 2019-08-20
EP3363433A1 (en) 2018-08-22
JP2018184463A (ja) 2018-11-22
IL313596A (en) 2024-08-01
SI3815684T1 (sl) 2025-01-31
US9693986B2 (en) 2017-07-04
US9623001B2 (en) 2017-04-18
DK3363433T3 (da) 2021-03-08
CA2877514C (en) 2025-11-25
CY1123749T1 (el) 2022-05-27
CN104582698A (zh) 2015-04-29
CA3067012C (en) 2021-10-05
EP4338805A3 (en) 2024-05-22
EP4556073A3 (en) 2025-07-30
MY187464A (en) 2021-09-23
DK4338805T3 (da) 2025-09-01
US9610272B2 (en) 2017-04-04
DK4342546T3 (da) 2025-09-01
PL4338805T3 (pl) 2025-09-29
MX378496B (es) 2025-03-11
UA128280C2 (uk) 2024-05-29
US10576054B1 (en) 2020-03-03
US20170119723A1 (en) 2017-05-04
US9918954B2 (en) 2018-03-20
JP2020073492A (ja) 2020-05-14
US10278936B2 (en) 2019-05-07
CA3067012A1 (en) 2014-01-03
EP2866801A2 (en) 2015-05-06
EP4342546A3 (en) 2024-05-22
PL3815684T3 (pl) 2025-01-20
IL275396B1 (en) 2024-07-01
US10016386B2 (en) 2018-07-10
EP4342546A2 (en) 2024-03-27
EP3815684A1 (en) 2021-05-05
RS67161B1 (sr) 2025-09-30
US10792270B2 (en) 2020-10-06
CO7190236A2 (es) 2015-02-19
LT3363433T (lt) 2021-02-25
DOP2014000301A (es) 2015-06-30
HUE072482T2 (hu) 2025-11-28
FI3815684T3 (fi) 2024-09-30
ES2993235T3 (en) 2024-12-26
IL275396B2 (en) 2024-11-01
US20170035722A1 (en) 2017-02-09
RS67162B1 (sr) 2025-09-30
LT3815684T (lt) 2024-11-25
AU2018204499A1 (en) 2018-07-12
US20200069632A1 (en) 2020-03-05
US20180289657A1 (en) 2018-10-11
RS61557B1 (sr) 2021-04-29
MX2020002907A (es) 2022-05-30
US10278939B2 (en) 2019-05-07
IL236376A0 (en) 2015-02-26
US9693984B2 (en) 2017-07-04
PT4342546T (pt) 2025-09-01
ES3040261T3 (en) 2025-10-29
AU2013282394A1 (en) 2015-01-22
SG11201408769QA (en) 2015-01-29
US10568861B1 (en) 2020-02-25
MX2020013933A (es) 2022-11-23
SI4342546T1 (sl) 2025-11-28
MA66493A1 (fr) 2025-11-28
LT4342546T (lt) 2025-09-10
EA201500069A1 (ru) 2015-04-30
MX2020013922A (es) 2022-08-15
US10278938B2 (en) 2019-05-07
US20190321323A1 (en) 2019-10-24
FI4342546T3 (fi) 2025-09-09
US20170258753A1 (en) 2017-09-14
EP4338805A2 (en) 2024-03-20
BR112014032905B1 (pt) 2022-02-22
WO2014005013A2 (en) 2014-01-03
AU2020294210A1 (en) 2021-01-28
US20180153846A1 (en) 2018-06-07
US20190192472A1 (en) 2019-06-27
HRP20241269T1 (hr) 2025-06-20
ES3040240T3 (en) 2025-10-29
HRP20210309T1 (hr) 2021-04-02
GEP201706768B (en) 2017-11-10
EP4556073A2 (en) 2025-05-21
PH12014502849A1 (en) 2015-02-23
ECSP15002815A (es) 2017-03-31
SG10201913646PA (en) 2020-03-30
MX2020008890A (es) 2022-08-15
US20170056361A1 (en) 2017-03-02
US10894028B2 (en) 2021-01-19
CA2877514A1 (en) 2014-01-03
SMT202500325T1 (it) 2025-11-10
SMT202100220T1 (it) 2021-05-07
SI4338805T1 (sl) 2025-11-28
SMT202400504T1 (it) 2025-01-14
US20180289658A1 (en) 2018-10-11
EA039108B1 (ru) 2021-12-06
NZ727849A (en) 2018-06-29
UA118015C2 (uk) 2018-11-12
EP4338805B1 (en) 2025-06-04
EA029988B1 (ru) 2018-06-29
US20200163925A1 (en) 2020-05-28
EP3363433B1 (en) 2020-12-09
SG10201913645RA (en) 2020-03-30
NZ743714A (en) 2019-08-30
LT4338805T (lt) 2025-09-25
US10555924B2 (en) 2020-02-11
CU20140151A7 (es) 2016-03-31
US20170143658A1 (en) 2017-05-25
CA3067008A1 (en) 2014-01-03
US20200078329A1 (en) 2020-03-12
US20200113864A1 (en) 2020-04-16
NZ743706A (en) 2019-08-30
PT4338805T (pt) 2025-09-02
HUE072535T2 (hu) 2025-11-28
NZ703267A (en) 2017-01-27
HUE053111T2 (hu) 2021-06-28
CN111840269A (zh) 2020-10-30
US20180289659A1 (en) 2018-10-11
EP3815684B1 (en) 2024-09-04
CN111840268A (zh) 2020-10-30
EP2866801A4 (en) 2016-02-10
KR20150036252A (ko) 2015-04-07
ES2846176T3 (es) 2021-07-28
SMT202500326T1 (it) 2025-11-10
US9918955B2 (en) 2018-03-20
MX394764B (es) 2025-03-24
US20200038358A1 (en) 2020-02-06
JP2015522029A (ja) 2015-08-03
HK1204271A1 (en) 2015-11-13
US20170258754A1 (en) 2017-09-14
CN111166736A (zh) 2020-05-19
US10555925B1 (en) 2020-02-11
HUE069516T2 (hu) 2025-03-28
US20200038359A1 (en) 2020-02-06
AU2020294210B2 (en) 2024-06-13
US10278935B2 (en) 2019-05-07
WO2014005013A3 (en) 2014-02-20
US20150157592A1 (en) 2015-06-11
US10278937B2 (en) 2019-05-07
TN2014000540A1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
PT3815684T (pt) Métodos de redução do risco de um episódio cardiovascular num indivíduo em terapia com estatina
DK3550571T3 (en) Negative Ion-Based Beam Injector
GB2519017B (en) Next instruction access intent instruction
GB2507498B (en) Secure computing environment
EP2800530A4 (en) TRANSFORMERS FOR HISTOTRIPSIA THERAPY
BR112013033974A2 (pt) terapia de combinação
EP2825100A4 (en) DEVICE FOR OPENING THE BREAST BASKET
BR302013000141S1 (pt) Configuração aplicada em copo
EP2949152A4 (en) COMPARING ACCESS POINTS LOADS
GB201222978D0 (en) An extract-transform-load processor controller
GB2484178B (en) Dynamic finger fixator
EP2862952A4 (en) Aluminum alloy plate
DE112013002562A5 (de) Nockenwelleneinheit
EP2721788A4 (en) METHOD AND ARRANGEMENT FOR SENDING QUESTIONS
DE112013001038A5 (de) Kugel-Schaft-Verbindung
EP2844043A4 (en) PLASMA GENERATOR (VARIANTS)
BR302012005794S1 (pt) Configuração aplicada em coroa
AU2012101555A4 (en) An Indentification Game
GB201211778D0 (en) Saddle tracker
GB201217017D0 (en) Secure access
ES1075603Y (es) Objeto terapeutico
GB201221326D0 (en) Novel treatments
GB201222665D0 (en) Secure computing system
GB201214582D0 (en) Internal framework
GB201222497D0 (en) Fermentation enclosure